#BreastCancerResearch

www.genengnews.com

Cancer Cells Cooperate to Obtain Nutrients from the Environment

Researchers propose that CNDP2-mediated cooperation can be an effective and specific target for cancer treatment.

link.springer.com

Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models - Breast Cancer Research

Background Epidemiological studies associate an increase in breast cancer risk, particularly triple-negative breast cancer (TNBC), with lack of breastfeeding. This is more prevalent in African America...

scitechdaily.com

Scientists Discover Plant Compound That Forces Aggressive Breast Cancer Cells Into Self-Destruction

oncodaily.com

Can a Vaccine Conquer Ovarian Cancer? Find Out at BGICC 2025 Cairo - OncoDaily

Can a Vaccine Conquer Ovarian Cancer? Find Out at BGICC 2025 Cairo / 17th BGICC Conference, advanced-stage ovarian cancer, Ahmed Ashour, BGICC, BGICC 2025,

doi.org

Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer | Nature Communications

The targeting of cancer stem cells (CSCs) has proven to be an effective approach for limiting tumor progression, thus necessitating the identification of new drugs with anti-CSC activity. Through a high-throughput drug repositioning screen, we identify the antibiotic Nifuroxazide (NIF) as a potent anti-CSC compound. Utilizing a click chemistry strategy, we demonstrate that NIF is a prodrug that is specifically bioactivated in breast CSCs. Mechanistically, NIF-induced CSC death is a result of a synergistic action that combines the generation of DNA interstrand crosslinks with the inhibition of the Fanconi anemia (FA) pathway activity. NIF treatment mimics FA-deficiency through the inhibition of STAT3, which we identify as a non-canonical transcription factor of FA-related genes. NIF induces a chemical HRDness (Homologous Recombination Deficiency) in CSCs that (re)sensitizes breast cancers with innate or acquired resistance to PARP inhibitor (PARPi) in patient-derived xenograft models. O

oncodaily.com

Is oligometastatic breast cancer curable? - OncoDaily

Is oligometastatic breast cancer curable? / Breast Cancer, cancer, NRG-BR002 trial, OncoDaily, Oncology, Paolo Tarantino, Stephen Chia

doi.org

Complex rearrangements fuel ER+ and HER2+ breast tumours | Nature

Breast cancer is a highly heterogeneous disease whose prognosis and treatment as defined by the expression of three receptors—oestrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor 2 (HER2; encoded by ERBB2)—is insufficient to capture the full spectrum of clinical outcomes and therapeutic vulnerabilities. Previously, we demonstrated that transcriptional and genomic profiles define eleven integrative subtypes with distinct clinical outcomes, including four ER+ subtypes with increased risk of relapse decades after diagnosis1,2. Here, to determine whether these subtypes reflect distinct evolutionary histories, interactions with the immune system and pathway dependencies, we established a meta-cohort of 1,828 breast tumours spanning pre-invasive, primary invasive and metastatic disease with whole-genome and transcriptome sequencing. We demonstrate that breast tumours fall along a continuum constrained by three genomic archetypes. The ER+ high-risk integra